CHEK2 and breast cancer: Germline pathogenic/likely pathogenic variants (GPVs) in CHEK2 are typically associated with a moderately increased risk of breast cancer in females [1,2,3,4,5,6,7], generally in the range of 20–30% lifetime risk of breast cancer and a relative risk (RR) of >2 [4,7,8,9].